What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
BACKGROUND:It is unclear what to do when people with type 2 diabetes have had no or a limited glycemic response to a recently introduced medication. Intra-individual HbA1c variability can obscure true response. Some guidelines suggest stopping apparently ineffective therapy, but no studies have addr...
| Autors principals: | , , , , , , |
|---|---|
| Altres autors: | |
| Format: | Journal article |
| Idioma: | English |
| Publicat: |
BioMed Central
2019
|